The standard first-line treatment for a patient with locally advanced NSCLC without actionable genomic alterations (AGA), according to the guidelines of all oncology associations, is immunotherapy, delivered as a monotherapy or in combination with platinum-based chemotherapy, depending on programmed death-ligand 1 (PD-L1) expression [2,3]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.